Oncology company BeOne Medicines Ltd (Nasdaq: ONC) (HKEX: 06160) (SSE: 688235) reported on Wednesday that it has received US Food and Drug Administration (FDA) Priority Review for its application to use BRUKINSA (zanubrutinib) with rituximab to treat adults with previously untreated mantle cell lymphoma. If approved, the combination would be the first and only chemotherapy-free, BTK inhibitor-based regimen for this patient group.
The application is supported by the Phase 3 MANGROVE trial, in which the combination reduced the risk of disease progression or death by 43% compared with standard treatment using bendamustine plus rituximab. The study met its primary endpoint of progression-free survival, with no new safety signals identified.
Full MANGROVE results will be presented at the Plenary Scientific Session of the 68th American Society of Hematology Annual Meeting on 13 December 2026. BeOne has also submitted an application to the European Medicines Agency, while China's National Medical Products Administration has accepted the filing for review.
BRUKINSA is currently approved in the US for adults with relapsed or refractory mantle cell lymphoma and several other B-cell malignancies.
CHOSA Oncology signs US laboratory agreement for Platin-DRP commercialisation
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma
Pentixapharm advances preparationsfor Phase 3 PANDA study
CStone and Kimia Therapeutics collaborate to advance oncology drug candidate
Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia
Lytix Biopharma's ruxotemitide combination meets primary endpoint in Phase II melanoma trial
INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP
Phrontline Biopharma reports preliminary safety and antitumour activity for TJ101
TME Pharma signs exclusive negotiation agreement with Japan's TMS for NOX-A12 rights
Evogene targets acute graft-versus-host disease for AI-driven drug discovery programme
Genmab reports 50% reduction in risk of death in Phase 3 head and neck cancer trial
Novocure and Verastem to evaluate combination therapy for pancreatic cancer
US WorldMeds acquires Orbus Therapeutics
Astellas and Audax Biosciences sign exclusive option and licence agreement for DAX-044
Thor Medical signs three-year isotope supply agreement with Medicines Discovery Catapult